Assisted Reproduction Industry, Cost and Access

Prevalence and performance of private equity-affiliated fertility practices in the United States

Borsa A, Bruch JD

Published January 2022 Fertility and sterility
DOI 10.1016/j.fertnstert.2021.08.035 PMID 34538462 PMC PMC8714667

RRM Academy Synopsis

Private equity clinics performed 29.3% of US ART cycles in 2018

In a national study of the CDC's 2018 data on 453 US fertility clinics, investor-backed clinics performed 29.3% of all 305,883 ART cycles among them. Success rates in women under 35 did not differ significantly between the two kinds of clinic. Genetic testing of embryos was more common at investor-backed clinics, and male-factor cycles were less common.

Key Findings

  • Of the 453 reporting practices, 66 had a private equity affiliation.
  • Private equity-affiliated practices performed 89,535 (29.3%) of the 305,883 ART cycles reported across the 453 practices.
  • Percent of transfers resulting in live births in women under 35 was 51.40 at private equity-affiliated and 48.04 at other practices; adjusted difference 2.43 (−0.69, 5.55), corrected P > 0.99.
  • The share of cycles done for a male-factor reason was 6.75% less (−10.15%, −3.36%; P=0.001) at private equity-affiliated practices.
  • Transfers using any preimplantation genetic testing were 10.60% more frequent in patients under 35 (3.49, 17.76; P=0.05) at private equity-affiliated practices.

Interpretation

The result is a one-year, practice-level snapshot of private equity market share, services and success rates in CDC data from 2018. The data capture clinics at a single point in time and do not follow practices after a purchase, and clinics report to the CDC without saying whether they belong to a larger network. The CDC data hold no relevant patient demographics. The authors say their findings likely understate the current investor share.

RRM Context

The authors cite high profit margins for IVF as one reason investors buy fertility clinics. IVF bypasses infertility and leaves the cause unresolved. Restorative reproductive medicine searches for the cause in both partners. Unexplained infertility means the cause stayed undiagnosed.

Abstract

Objective

To quantify the proportion of annual assisted reproductive technology (ART) cycles performed at private equity-affiliated fertility practices and to test for differences in services and success rates between private equity-affiliated and nonaffiliated practices.

Design

Cross-sectional analysis of national data set.

Setting

Not applicable.

Patients

None.

Interventions

Not applicable.

Main Outcome Measures

The primary outcome measures were the volume of ART cycles performed, the percentage of retrievals resulting in live births, and the percentage of transfers resulting in live births. The secondary outcomes included the median income of the practice location, the use of preimplantation genetic testing, the clinical service availability, and the patient reasons for seeking treatment.

Results

Of the practices listed on the Centers for Disease Control's 2018 Fertility Clinic Success Rates Report, 14.7% had a private equity affiliation. Of the 305,883 ART cycles performed in 2018, 29.3% (89,535) occurred at private equity-affiliated practices. Patients at private equity-affiliated practices were 6.75% (95% confidence interval [CI], -10.15%, -3.36%) less likely to initiate a cycle due to male factor infertility, and 10.60% (95% CI, 3.49, 17.76) more likely to use preimplantation genetic testing before embryo transfer. No statistically significant differences were found in success rates among women aged <35 years. The average median household income (standard error) in zip codes with private equity-affiliated practices compared with nonaffiliated practices was $83,610 ($35,990) and $72,161 ($32,314), respectively.

Conclusions

A major portion of fertility practices in the United States are private equity-affiliated, and these practices perform an even greater portion of ART cycles in the United States each year. Fertility appears to be the medical specialty with the greatest market share owned by private equity. Our findings corroborate preliminary research, which forecasts the increasing involvement and consolidation by private equity in fertility. Future research should continue monitoring for differences in outcomes, financing, case mix, service use, and accessibility.

Topics

By this author

Related research

Assisted Reproduction › Industry, Cost and Access › Money Flows and Financial Incentives
Alexander Borsa, Joseph Dov Bruch
Alex Borsa, A Borsa, Joe Bruch, Joey Bruch, J Bruch
PMID 34538462 34538462 DOI 10.1016/j.fertnstert.2021.08.035 10.1016/j.fertnstert.2021.08.035 Borsa et al. 2022, Borsa 2022